ArticleMolecular therapy. Methods & clinical development2023
Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells.
Article in Molecular therapy. Methods & clinical development, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Impact of cryopreservation on PBMC-derived CAR-T cell manufacturing outcomes: a systematic review.Frontiers in immunology · 2026Pooled it
- Autofluorescence imaging reveals the impact of cryopreservation on T cell metabolism and activation response.Molecular therapy. Advances · 2026Article
- Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies.Cytotherapy · 2026Article
- From cold chain to ambient: Benefits, risks, and evidence across cell therapy logistics.Molecular therapy. Methods & clinical development · 2025Review
- International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.Blood advances · 2025Article
- Autofluorescence imaging reveals the impact of cryopreservation on T cell metabolism and activation response.bioRxiv : the preprint server for biology · 2025Article
- Cryopreserved leukapheresis enables scalable and distributed CAR-T manufacturing: a multi-platform comparative study.Scientific reports · 2025Article
- High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Advances in manufacturing chimeric antigen receptor immune cell therapies.Seminars in immunopathology · 2024Review
- Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers.Experimental hematology & oncology · 2024Review
- Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation.Nature communications · 2024Article
- Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output.Molecular therapy. Methods & clinical development · 2024Article
- Post-thaw application of ROCK-inhibitors increases cryopreserved T-cell yield.RSC medicinal chemistry · 2023Article
- Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating.Cancer discovery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Cryopreservation of chimeric antigen receptor (CAR) T cells facilitates shipment, timing of infusions, and storage of subsequent doses. However, reports on the impact of cryopreservation on CAR T cell efficacy have been mixed. We retrospectively compared clinical outcomes between patients who received cryopreserved versus fresh CAR T cells for treatment of B cell leukemia across two cohorts of pediatric and young adult patients: those who received anti-CD22 CAR T cells and those who received bispecific anti-CD19/22 CAR T cells. Manufacturing methods were consistent within each trial but differed between the two trials, allowing for exploration of cryopreservation within different manufacturing platforms. Among 40 patients who received anti-CD22 CAR T cells (21 cryopreserved cells and 19 fresh), there were no differences in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.